praxismedicines.com - PRAX Operating profit before amortization
Geopolitical instability could disrupt the supply of components for Praxis Precision Medicines (PRAX) therapies. This operating profit trend captures these risks, where the 0.00 mark indicates the current income level. The business foundation is based on venture cash burn to secure a future CNS monopoly, while the colossal, underserved demand for epilepsy treatments confirms the high growth potential of Praxis Precision Medicines (PRAX).
%20Operating%20profit%20EBITDA&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_PRAX_-_Praxis-Precision-Medicines_-_Operating-profit-EBITDA "Praxis Medicines - PRAX Operating income before deduction of amortization (period 11/23/2025 - 11/12/2026) | 👁️GURU.Markets👁️")
Summary analytical data breakdowns for Praxis Precision Medicines, Inc. (PRAX)
- market price and analyst price targets:
- issuer market value details:
- balance sheet net asset value indicators:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Praxis Precision Medicines|PRAX - Long-Term Debt to Equity|Current Liabilities to Equity Praxis Precision Medicines Inc|PRAX - Company Debts|Debt to Net Assets Ratio Praxis Precision Medicines|PRAX - Company Long-Term Debts|Short-Term Debt Praxis Precision Medicines|Quick Liquidity Indicator praxismedicines.com
- company profitability and valuation multiples indicators:
PRAX - Net Profit|Company Profit Forecast Praxis Precision Medicines|PRAX - Price to Earnings Ratio|Market Cap to Projected Earnings praxismedicines.com|PRAX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Praxis Precision Medicines|PRAX - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Praxis Precision Medicines|PRAX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months praxismedicines.com|PRAX - Net earnings per share growth this year|Expected earnings per share trend next year Praxis Precision Medicines
Analysis of all company metrics:Praxis Corp
For Praxis Precision Medicines (PRAX), operating profit dynamics reflect the financial foundation of its epilepsy drug development. This indicator captures the actual cash flow from core operations, stripped of financial and tax factors. The metric calculates the difference between revenue and operating expenses, measuring the efficiency of resource management. Amid an intensive R&D pipeline, this figure demonstrates the company's ability to sustain clinical trials. The stability of the trend confirms the capital's resilience to market volatility.
Who Praxis Precision Medicines competes with
Operating profit EBITDA Biogen Idec BIIB|NBIX: Operating profit before deduction of amortization|RGC (regencellbioscience.com) - Operating profit before amortization|AXSM: Operating profit EBITDA|ACAD - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Xenon Pharmaceuticals Inc|Viking Therapeutics Corp (VKTX) - Operating income before deduction of amortization|Operating profit before deduction of amortization SUPN (Supernus Pharmaceuticals)|CPRX (catalystpharma.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Denali Therapeutics Inc. DNLI|HRMY (Harmony Biosciences Inc) - Profit before deduction of interest, taxes, depreciation and amortization|BHVN - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization AMLX (Amylyx Corp)|TRVI: Operating profit EBITDA|Profit before interest, taxes and amortization anavex.com (AVXL)|CBLL (CeriBell) - Operating profit EBITDA|Operating profit before deduction of amortization Prothena Corporation PLC (PRTA)|Operating profit EBITDA ALEC|Operating income before deduction of amortization Annexon Biosciences Inc.|Profit before payment of interest, taxes and amortization Omeros OMER|Operating income before deduction of amortization neurogene.com (NGNE)|AC Immune SA - Operating profit EBITDA|Operating income before deduction of amortization Voyager Therapeutics Inc VYGR|Neumora Therapeutics Inc (NMRA) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Scilex Holding Company, Inc. (SCLX)|Profit before payment of interest, taxes and amortization Tevogen Bio Holdings|Operating profit before amortization ACOG (Alpha Cognition Corp)|Operating profit before deduction of amortization CGTX (Cognition Therapeutics, Inc.)|IKT (Inhibikase Therapeutics Inc) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Cassava SAVA|ASRT - Operating profit before deduction of amortization|Coya - Operating profit EBITDA|Profit before interest, taxes and amortization Vistagen Therapeutics|OVID: Operating profit EBITDA|Operating profit before amortization ABOS|CRVO (CervoMed Inc) - Operating profit EBITDA|Alterity Therapeutics Ltd (ATHE) - Operating income before deduction of amortization|Operating profit EBITDA CLNN|Operating profit before deduction of amortization pepgen.com PEPG|Operating profit EBITDA JUNS (Jupiter Neurosciences)|Operating income before deduction of amortization Relmada Therapeutics Inc (RLMD)|ANVS - Profit before payment of interest, taxes and amortization|GRCE (Grace Therapeutics, Inc.) - Operating profit before amortization|AIFF: Operating profit EBITDA|Profit before interest, taxes and amortization Klotho Neurosciences (KLTO)|Profit before payment of interest, taxes and amortization NeuroSense Therapeutics Ltd|Reviva Pharmaceuticals Holdings Inc. (RVPH) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization MetaVia Inc (MTVA)|NRXS: Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Helius Medical Technologies HSDT|Income before deduction of interest, taxes and amortization PASG|Neuphoria - Operating profit EBITDA|NERV - Operating profit EBITDA|ATHA (Athira) - Operating profit before deduction of amortization|Operating profit before amortization ADXN|Profit before payment of interest, taxes and amortization Alzamend Neuro Inc.|Operating profit before amortization CYCN (Cyclerion)|Operating profit EBITDA PTIX|KTTA - Profit before interest, taxes and amortization|Cortigent - Operating profit before deduction of amortization|Operating profit EBITDA Avenue Therapeutics Inc ATXI|BCLI - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization CARA (caratherapeutics.com)|Chromocell Therapeutics Corp. (CHRO) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Eliem Therapeutics Inc. (ELYM)|Profit before payment of interest, taxes and amortization Intra-Cellular Therapies Inc.|Longboard - Profit before deduction of interest, taxes, depreciation and amortization|Profit before payment of interest, taxes and amortization Marinus Pharmaceuticals (MRNS)|NKGN (nkgenbiotech.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA NRBO (NeuroBo Pharmaceuticals, Inc.)|Operating profit EBITDA Sage Therapeutics Inc. SAGE|SNPX: Operating profit before deduction of amortization|TRVN (Trevena Inc) - Operating profit before amortization|VIGL: Operating profit EBITDA|WENA - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Cerevel Therapeutics, Inc.
